

Anavex Life Sciences

13:55 13 Dec 2018

Anavex Life Sciences doses patients in Phase 2 ANAVEX2-73 Parkinson disease dementia study

Anavex Life Sciences Corp (NASDAQ:AVXL) told analysts Wednesday that it has started enrolling and dosing patients for its phase two ANAVEX2-73 Parkinson's disease dementia (PDD) study.

The New York-based biotech's lead drug candidate ANAVEX 2-73 has already completed Phase 2a clinical trials for the treatment of Alzheimer's disease.

The drug is also in preclinical clinical trials to treat Rett Syndrome, a rare neurological disorder that occurs mainly in girls, epilepsy and Parkinson's disease dementia, a decline in reasoning that develops in many people living with Parkinson's a year after diagnosis.

READ: Anavex Life Sciences shares rise after FDA gives green light on Phase 2 trial

"We were pleased to report that we have successfully activated 100% of all planned clinical study sites representing 20 clinical trial sites for the Phase 2 ANAVEX2-73 Parkinson disease dementia study," Anavex Life Sciences CEO Christopher Missling told analysts on a call Wednesday.

"Enrollment and dosing of patients is currently proceeding as planned," he added.

The biopharma is proceeding with a phase two double-blind, randomized, placebo-controlled, 14-week safety and efficacy trial of ANAVEX2-73 for the treatment of Parkinson's disease dementia.

Missling said the company had also successfully initiated a novel genomic marker driven later-stage CNS precision medicine trial for Alzheimer's disease for ANAVEX2-73 entering fiscal 2019.

"The company has successfully activated 75% of all planned clinical study sites representing 9 clinical trial sites for the Phase 2b/3 ANAVEX2-73 Alzheimer disease study," said Missling indicating that enrollment and dosing of patients was currently proceeding as planned.

Earnings in focus

The biotech logged a net loss for the year of \$17.5 million, or \$0.39 per share, compared to a net loss of \$13.5 million, or \$0.33 per share for the comparative year.

The biotech said that it had cash and equivalents of \$22.9 million on its books as of September 30, 2018.

Shares of the biotech fell nearly 3.3% to \$2.05 Thursday in midday trade on a broad market pullback.

Price: 4.71

Market Cap: \$282.99 m

1 Year Share Price Graph



Share Information

Code: AVXL

Listing: NASDAQ

52 week	High	Low
	6.3	2.21

Sector: Pharma & Biotech

Website: www.anavex.com

Company Synopsis:

Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company engaged in the development of novel drug candidates to treat Alzheimer's disease, other CNS diseases and various types of cancer.

action@proactiveinvestors.com

Contact Uttara Choudhury at uttara@proactiveinvestors.com

Follow her on Twitter: [@UttaraProactive](https://twitter.com/UttaraProactive)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.